Scancell (SCLP) Share Price, News & Analysis

Company Overview

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.

Key Stats

• Today's Range: 15.50 to 16.50
• 50-Day Range: 11 to 16.25
• 52-Week Range: 7.86 to 16.50
• Volume: 2.71 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: £165.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCLP Stock Analysis - Frequently Asked Questions

How have SCLP shares performed this year?

Scancell's stock was trading at GBX 10.12 at the beginning of 2026. Since then, SCLP shares have increased by 57.6% and is now trading at GBX 15.95.

How were Scancell's earnings last quarter?

Scancell Holdings plc (LON:SCLP) announced its quarterly earnings results on Thursday, January, 29th. The company reported ($0.55) earnings per share for the quarter. Scancell had a negative net margin of 116.98% and a positive trailing twelve-month return on equity of 90.29%.

How do I buy shares of Scancell?

Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scancell investors own include KAZ Minerals (KAZ), Petropavlovsk (POG), Standard Chartered (STAN), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO) and Empyrean Energy (EME).

Company Calendar

• Last Earnings: 1/29/2026
• Today: 5/06/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SCLP
• CIK: N/A
• Web: www.scancell.co.uk
• Phone: +44-115-8231863
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£6.75 million
• Net Margins: -116.98%
• Pretax Margin: N/A
• Return on Equity: 90.29%
• Return on Assets: -45.28%

Debt

• Debt-to-Equity Ratio: -193.29
• Current Ratio: 0.56
• Quick Ratio: 13.01

Sales & Book Value

• Annual Sales: £4.71 million
• Price / Sales: 35.14
• Cash Flow: GBX 2.03 per share
• Price / Cash Flow: 7.86
• Book Value: GBX (0.39) per share
• Price / Book: -40.92

Miscellaneous

• Outstanding Shares: 1,037,781,000
• Free Float: N/A
• Market Cap: £165.53 million
• Optionable: Not Optionable
• Beta: 0.45